Cardiac resynchronization therapy significantly improved all SF-36 quality of life domains and 6MWT by ≥15% in heart failure patients over 12 months (p ≤ 0.001).
Does cardiac resynchronization therapy improve health-related quality of life in patients with heart failure meeting ESC indications?
Cardiac resynchronization therapy significantly improves health-related quality of life across all SF-36 subscales at 12 months in patients with heart failure.
Absolute Event Rate: 0% vs 0%
Purpose: To estimate the impact of cardiac resynchronization therapy (CRT) on health-related quality of life among patients with heart failure (HF). Methods: 40 patients (90 proc. males) mean 62,03 ± 10,46, meeting European Society of Cardiology recommended CRT implantation indications were included into this study. The study lasted for 12 months. Health-related quality of life was evaluated using the Medical Outcomes Study 36-item Short Form (SF-36) questionnaire at baseline and after 6 and 12 months post – CRT. 6-minute walk test (6 MWT) and New York Heart Association (NYHA) functional class were used for clinical evaluation. Statistical analysis was performed using SPSS version 19.0. A value of p < 0,05 was dened as statistically signicant. Results: Statistically signicant improvements were seen in all health - related quality of life questionnaire subscales after 12 months: physical functioning (PF) (30,69 ± 10,16 vs 38,66 ± 10,24, p = 0,0001), role limitations due to physical health (RP) (30,81 ± 5,70 vs 36,11 ± 10,78, p = 0,0001), role limitations due to emotional problems (RE) (31,88 ± 11,81 vs 40,57 ± 13,45, p = 0,0001), energy/fatigue (VT) (39,18 ± 10,64 vs 46,28 ± 9,64, p = 0,0001), emotional well being (MH) (36,13 ± 13,19 vs 43,34 ± 10,79, p = 0,001), social functioning (SF) (34,21 ± 10,32 vs 42,08 ± 10,01, p = 0,0001), bodily pain (BP) (38,89 ± 10,41 vs 48,35 ± 9,15, p = 0,0001), general health (GH) (31,97 ± 8,19 vs 38,28 ± 8,06, p = 0,0001), physical component summary (PCS) (30,46 ± 7,92 vs 37,58 ± 9,90, p = 0,0001) and mental component summary (MCS) (37,81 ± 11,25 vs 45,11 ± 10,51, p = 0,0001). Lower NYHA functional class group reported greater improvement on the PF (p = 0,044), SF (p = 0,0001), MH (p = 0,006), RE (p = 0,008), BP (p = 0,041) and MCS (p = 0,0001) after 12 months. The 6MWT augmentation ≥ 15 proc. was associated with signicant improvement in PF (p = 0,
Rinkūnienė et al. (Sat,) reported a other. Cardiac resynchronization therapy significantly improved all SF-36 quality of life domains and 6MWT by ≥15% in heart failure patients over 12 months (p ≤ 0.001).